← All trials
NCT00550797
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- Jul 1, 2008
- Completion date
- Oct 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- SyntaraLead sponsor
- University of AmsterdamOverall official - principal investigator
- University of PadovaOverall official - principal investigator
- University of PisaOverall official - principal investigator
- University of LondonOverall official - principal investigator
- OptumCollaborator
- Topigen Pharmaceuticals Inc.Study director
- University of ManchesterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.